A phase II study of concurrent docetaxel, epirubicin and cyclophospha-mide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 145-151

  Yao, Xin ^a   Hosenpud, Janet ^a   Chitambar, Christopher R ^a   Charlson, John ^a   Cheng, Yee Chung ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Breast cancer; Cyclophosphamide; Docetaxel; Epirubicin; Locally Ad vanced; Neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; HORMONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEATH; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDEMA; EYE IRRITATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HEART FAILURE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; INSOMNIA; LYMPH NODE; LYMPHOCYTOPENIA; MALE; MOOD CHANGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; RECURRENCE FREE SURVIVAL; RHINORRHEA; SIDE EFFECT; SINUSITIS; SYNCOPE; THORAX PAIN; URINARY TRACT INFECTION; VOMITING;

EID: 84881202664     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.3980     Document Type: Article

References (11)

1. von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vi-norelbine-capecitabine versus docet-axel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Can-cer Inst. 2008;100:542-551.
2. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785.
3. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel im-proves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin On-col. 2005;23:5983-5992.
4. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100:552-562.
5. Vogt UKD, Brandt B, Bosse U, Bonk U, Assen AVD, Muhs HJ, Schlotter CM. Semi-quantitative gene expression profiling for therapy prediction in a breast cancer neoadjuvant therpay ap-plying docetaxel/epirubicin/cyclophosphamide. ASCO Annual Meeting Proceedings 2007;25(18S):21144.
6. Bear HD, Anderson S, Brown A, et al. The effect on tumor re-sponse of adding sequential preoperative docetaxel to pre-operative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
7. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
8. Buzdar AU. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol. 2006;24:2409-2411.
9. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer. 2003;4:179-186.
10. Toi M, Nakamura S, Kuroi K, et al. Phase II study of preopera-tive sequential FEC and docetaxel predicts of pathological re-sponse and disease free survival. Breast Cancer Res Treat. 2008;110:531-539.
11. Rody A, Karn T, Gatje R, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007;16:86-93.